Proactive Investors - Run By Investors For Investors

Aptinyx stock falls after NYX-2925 trial for treating painful diabetic nerve damage fails to meet endpoint

However, the biotech said it will still conduct an exploratory Phase 2 study of NYX-2925 for treating patients with fibromyalgia or muscle pain
Researchers working in a lab
The Evanston, Illinois-based clinical-stage company develops therapies for disorders of the brain and nervous system

Shares in Aptinyx Inc (NASDAQ:APTX) tumbled Wednesday after the biotech disclosed that the Phase 2 study of its treatment for painful diabetic peripheral neuropathy (DPN), which is nerve damage caused by high blood sugar, did not meet its primary endpoint.

The Evanston, Illinois-based biotech’s therapy, did not show a significant difference in patients' daily pain scores compared to placebo.

“This four-week proof-of-concept study of our novel NMDA receptor modulator, NYX-2925, in painful DPN was designed to evaluate a 20-fold dose range, determine whether efficacy and dose response could be observed on primary and secondary endpoints, and assess safety in a patient population,” said Aptinyx CEO Norbert Riedel. “While the study did not meet its primary endpoint, we observed improvements on multiple measures, differential activity across dose levels, and a very favorable safety profile.”

READ: Valens GroWorks aims to capture a higher-level market in the cannabis extract space

The stock fell more than 73% to $4.78 in afternoon trade.

The company, however, said it is still conducting an exploratory Phase 2 study of NYX-2925 in patients with fibromyalgia or widespread muscle pain and tenderness. It said a full analysis of the data should be available in the first half of 2019.

The clinical-stage company develops therapies for disorders of the brain and nervous system. Allergan plc (NYSE:AGN) recently acquired its depression drug AGN-241751 for further development.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

View full APTX profile View Profile

Aptinyx Inc Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use